Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Baird Medical Investment Holdings (BDMD) Accumulated Expenses (2023 - 2025)

Baird Medical Investment Holdings has reported Accumulated Expenses over the past 3 years, most recently at $678214.0 for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 15.0% year-over-year to $678214.0; the TTM value through Dec 2025 reached $678214.0, down 15.0%, while the annual FY2025 figure was $678214.0, 15.0% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $678214.0 at Baird Medical Investment Holdings, down from $693309.0 in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $797912.0 in Q4 2024 and troughed at $678214.0 in Q4 2025.
  • A 3-year average of $730017.5 and a median of $721972.0 in 2023 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: grew 6.3% in 2024 and later fell 15.0% in 2025.
  • Year by year, Accumulated Expenses stood at $750635.0 in 2023, then increased by 6.3% to $797912.0 in 2024, then fell by 15.0% to $678214.0 in 2025.
  • Business Quant data shows Accumulated Expenses for BDMD at $678214.0 in Q4 2025, $693309.0 in Q2 2025, and $797912.0 in Q4 2024.